(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) dropped 33.96% over 21 sessions, from EUR0.53 on October 12th to EUR0.35 at 02:33 EST on Saturday – marking four consecutive sessions of losses for this stock. NASDAQ, however, is currently up 2.05% to EUR13,798.111 after experiencing a downward trend during previous session; Inovio Pharmaceuticals last closing price was EUR0.36, 86.13% lower than its 52-week high of EUR2.61.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing DNA medicines to treat and prevent diseases caused by HPV, cancer and infectious diseases. Through SynCon and CELLECTRA technologies, Inovio creates personalized DNA sequences designed to target antigens accurately while effectively delivering DNA plasmids into patients. Their pipeline of treatments for conditions related to HPV infection includes cervical dysplasia; cervical, vulvar and anal dysplasia as well as respiratory papillomatosis; GBM; Ebola virus disease and Lassa fever among others.
Inovio collaborates with many partners and institutions, such as Advaccine Biopharmaceuticals, ApolloBio Corporation, AstraZeneca, and the Bill & Melinda Gates Foundation – among many others. Established in 1983 and located in Plymouth Meeting Pennsylvania.
Yearly Analysis
Inovio Pharmaceuticals is a biotechnology company focused on creating DNA-based immunotherapies and vaccines. Based on available information, here is an investment outlook for investors:
Yearly Top and Bottom Values:
Inovio Pharmaceuticals’ stock is currently trading at EUR0.35, which equals its 52-week low. This shows that Inovio has been on a decline throughout this year; investors should use caution before investing in this stock as it could continue its downward spiral.
Anticipated Sales Growth:
Inovio Pharmaceuticals’ sales growth is forecast to drop significantly this year and next, which could put strain on its profitability and investment capacity in research and development projects.
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Inovio Pharmaceuticals’ EBITDA currently stands at 2.14; this indicates positive cash flow from its operations and should continue for some time; however given negative sales growth it remains to be seen how long this positive cash flow can persist.
Overall, investors should proceed with caution when investing in Inovio Pharmaceuticals. Negative sales growth and current stock price indicators suggest an expected decline in performance for the company; although its positive EBITDA offers some reassurance to investors. Before making their final decision about investing, investors should carefully assess Inovio Pharmaceuticals’ long-term prospects before making their commitment.
Technical Analysis
At present, Inovio Pharmaceuticals (INO) stock price stands at EUR0.39 which is significantly below both its 50-day moving average of EUR0.42 and 200-day moving average of EUR0.74. Additionally, its current volume stands 18.71% lower than average volume of 3400710.
As for volatility, INO experienced an intraday variation of negative 1.87% over the last week, negative 1.64% for last month and positive 3.85% variation over last quarter; its highest amplitude of average volatility over those timeframes was 1.87% for week-to-week variance and 3.99% (month to month and quarter respectively).
According to the stochastic oscillator, INO’s stock may currently be considered overbought (>=80), signaling it may be time for a correction.
Overall, INO’s current price falls beneath its moving averages and is experiencing high volatility. Investors should carefully monitor its price movements and consider taking a cautious approach before investing.
Quarter Analysis
Inovio Pharmaceuticals’ recent sales growth has been negative, experiencing an 80.6% decrease this quarter and projecting moderate annualized growth estimates of 12.9% for next quarter; however, its estimates for current quarter and subsequent ones are more upbeat: 13.3% and 38.1%, respectively.
Even with its recent decline in year-on-year quarterly revenue growth of 71.2%, this company still maintained an estimated trailing twelve month revenue of 9.62M; suggesting it managed to maintain a stable revenue stream in spite of difficulties it has encountered.
Overall, Inovio Pharmaceuticals appears to be experiencing some short-term challenges; however, their growth projections for the coming quarters indicate they could experience expansion soon enough. As with any investment decision, it is wise to carefully consider all relevant factors and consult a financial advisor before making your own investment decisions.
Equity Analysis
Inovio Pharmaceuticals currently boasts a dividend yield of 1.52%, which is relatively low compared to other stocks on the market. This may be an indicator that management does not prioritize dividend payments to shareholders and should be taken into consideration when assessing potential return.
The company reported an EPS of EUR-0.63, which indicates negative earnings over its trailing twelve month period and may cause concern to some investors.
Return on Equity (ROE) for the twelve trailing months for this company stands at an abysmal negative -72.13%, an indicator that they may be failing to generate profits efficiently relative to shareholder’s equity. This may cause investors concern as it suggests they may not be using assets effectively to generate profits and thus could potentially face loss of investment returns as a result of poor asset utilization and return.
Overall, investors should take care to consider all relevant information when making an investment decision about Inovio Pharmaceuticals. Seeking professional advice may also be worthwhile before making their final choice.
More news about Inovio Pharmaceuticals (INO).
